Denali signs Lonza to make biologics in first CMO deal

By Flora Southey

- Last updated on GMT

GettyImages/digicomphoto
GettyImages/digicomphoto

Related tags Gene expression Amyotrophic lateral sclerosis

Lonza has inked a biologics deal with Denali to make neurodegenerative disease therapies, offering the Californian firm opportunity to have production “on their back doorstep.”

The firms announced the partnership – covering all stages of development manufacturing for clinical trials – for diseases such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).

Lonza Group will also be responsible for delivering finished drug products for patients, overseen by its in-house Drug Product Services in Basel, Switzerland.

“This is Denali’s first portfolio of drugs, and we will be their first clinical manufacturer,” ​said Lonza's Karen Fallen.

Fallen said the initial development work will be carried out at the contract manufacturing organisation’s (CMO’s) clinical development facility in Slough, UK.

“Denali will then have the option to produce clinical material in both Slough, UK and Hayward, CA, US.

“As Denali are based in California, they have the option of having production ‘on their back doorstep’ if needed,” ​she told us.

The Swiss CMO acquired the Hayward manufacturing facility from Shire in October last year​, to cater for demand for mammalian cell culture-based drug production.

The site added early-phase clinical manufacture on the West Coast, as a complement to Lonza’s Slough facilities, said Fallen.

Denali said the partnership enables access to Lonza’s GS Xceed Gene Expression System, which the CMO claims creates cell lines up to six weeks, encourages improved cell growth, and faster doubling times than its predecessor.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers